A Phase 1 Dose Escalation and Expansion Study Of SHR-1916 In Subjects With Locally Advanced Or Metastatic Solid Tumors

NCT04842630 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

11

Enrollment

INDUSTRY

Sponsor class

Stopped R\&d strategy adjustment

Conditions

Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG: SHR-1916

Sponsor

Jiangsu HengRui Medicine Co., Ltd.